A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg alone and Seretide 50/500mcg alone) in the treatment of subjects with COPD The primary objective of the study is to compare the effects of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily with the individual treatments (tiotropium bromide 18mcg once da...

• Country None
• organs None
• Specialty None

A study of a new medicine, an intravenous antibiotic (GSK2251052) in adults, with complicated urinary tract infection or pyelonephritis To evaluate the safety and tolerability of GSK2251052 in the treatment of adult subjects with lower cUTI and pyelonephritis (complicated and uncomplicated). To evaluate the clinical and microbiologic...

• Country None
• organs None
• Specialty None

An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma We plan to assess the amount of [18F]ML-10 that is taken up by cancer cells undergoing programmed cell death or apoptosis. We will assess this after chemotherapy treatment in patients with Non Hodgki...

• Country None
• organs None
• Specialty None

A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD The primary objective of this study is to evaluate the efficacy and safety of three doses of GSK573719 (125, 250, and 500 mcg once daily) compared with placebo in subjects with COPD in order to inform...

• Country None
• organs None
• Specialty None

A study to test two investigational drugs, dabrafenib and trametinib, for treating melanoma To establish the superiority of dabrafenib and trametinib combination therapy over dabrafenib and trametinib placebo (dabrafenib monotherapy) with respect to progression-free survival (PFS) for subjec...

• Country None
• organs None
• Specialty None

A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma To investigate the effect of SB681323 on the clinical signs of neuropathic pain in patients with nerve trauma and/or compression

• Country None
• organs None
• Specialty None

Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma To evaluate the efficacy and safety of fluticasone propionate (FP)/ salmeterol xinafoate (SLM) HFA MDI 50/25 µg 1 or 2 inhalation twice daily for 8 weeks in comparison with FP HFA MDI 50 µg 1 or 2 inh...

• Country None
• organs None
• Specialty None

Evaluation of the safety and tolerability of re-dosing with intravenous (IV)otelixizumab in adult subjects with newly diagnosed type 1 diabetes mellitus To assess the safety, tolerability, and immunogenicity of re-dosing at 6 months with an 8-consecutive day series of otelixizumab intravenous (IV) infusions in adult subjects with newly diagnosed T1DM.

• Country None
• organs None
• Specialty None

Study of Fluticasone Furoate/Vilanterol in COPD, and the effects of Reducing Lung Over-Inflation on the Heart The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that treatment of lung deflation with FF/VI Inhalation Powder 100/2...

• Country None
• organs None
• Specialty None

A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days To assess the safety and tolerability of repeat inhaled doses of GSK233705B MgSt (inhaled twice daily for 7 days) in COPD patients.

• Country None
• organs None
• Specialty None